375
Participants
Start Date
March 30, 2017
Primary Completion Date
June 25, 2018
Study Completion Date
June 25, 2018
Placebo
Oral administration
Gabapentin enacarbil
Oral administration
Site JP00025, Nagoya
Site JP00029, Nagoya
Site JP00040, Nagoya
Site JP00006, Kitakyushu
Site JP00022, Kitakyushu
Site JP00002, Sapporo
Site JP00003, Sapporo
Site JP00004, Sapporo
Site JP00023, Sapporo
Site JP00041, Kawanishi
Site JP00005, Kobe
Site JP00038, Kawasaki
Site JP00007, Yokohama
Site JP00017, Yokohama
Site JP00049, Yokohama
Site JP00050, Yokohama
Site JP00009, Yokosuka
Site JP00032, Sakai
Site JP00043, Tokorozawa
Site JP00012, Arakawa City
Site JP00001, Chōfu
Site JP00028, Chōfu
Site JP00018, Chūō
Site JP00024, Chūō
Site JP00048, Meguro City
Site JP00034, Musashino
Site JP00046, Nakano City
Site JP00019, Ōta-ku
Site JP00011, Shibuya City
Site JP00013, Shinagawa
Site JP00015, Shinagawa
Site JP00016, Shinagawa
Site JP00008, Shinjuku
Site JP00014, Shinjuku
Site JP00021, Shinjuku
Site JP00031, Chiba
Site JP00036, Fukuoka
Site JP00020, Kyoto
Site JP00035, Kyoto
Site JP00010, Osaka
Site JP00026, Osaka
Site JP00037, Osaka
Site JP00039, Osaka
Site JP00047, Osaka
Site JP00030, Saitama
Site JP00044, Saitama
Lead Sponsor
Astellas Pharma Inc
INDUSTRY